This website is developed and sponsored by Consilient Health. This site has been developed as a source of medicine information for healthcare professionals or patients who have been prescribed Mysimba®

This website is not intended for the general public.

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2 | Tel: +353 1 6764971 | Fax: +353 1 6762517 Website: www.hpra.ie | e-mail: medsafety@hpra.ie

Adverse events should also be reported to Nalpropion Pharmaceuticals LLC: (800) 793-2145 or APV.AECurrax@primevigilance.com

For all other queries, please contact Consilient Health at Tel: +353 (0)1 2057760 | Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

POM Medicine

Product Authorisation Number: EU/1/14/988/001-002

MYS-0196-001-8/20

IE-MYS-146a  |  Date of preparation: December 2020

This website is developed and sponsored by Consilient Health. This site has been developed as a source of medicine information for healthcare professionals or patients who have been prescribed Mysimba®

This website is not intended for the general public.

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2 | Tel: +353 1 6764971 | Fax: +353 1 6762517 Website: www.hpra.ie | e-mail: medsafety@hpra.ie

Adverse events should also be reported to Nalpropion Pharmaceuticals LLC: (800) 793-2145 or APV.AECurrax@primevigilance.com

For all other queries, please contact Consilient Health at Tel: +353 (0)1 2057760 | Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

POM Medicine

Product Authorisation Number: EU/1/14/988/001-002

MYS-0196-001-8/20

IE-MYS-146  |  Date of preparation: October 2020

Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional. Please consult your doctor or nurse for further information.

This site has been developed as a source of information for healthcare professionals or patients who have been prescribed Mysimba®. This website is not intended for the general public. The information on this website is intended for Republic of Ireland residents only.

Mysimba® is a registered trademark of Nalpropion Pharmaceuticals LLC
© 2020 Nalpropion Pharmaceuticals LLC

Other trademarks, registered or otherwise, are the property of their respective owners.